In this session, we discussed the challenge of developing a new drug in the biomarker field area. So the agnostic indication, meaning the drug that is developed not for a specific cancer type, but for a specific biological group of tumors characterized by a similar molecular aberration. And what we discussed with Dr. Ralf Herold, who leads the regulatory science at EMA, is all the efforts this regulatory agency does to work with us to make new drugs available for our patients...
In this session, we discussed the challenge of developing a new drug in the biomarker field area. So the agnostic indication, meaning the drug that is developed not for a specific cancer type, but for a specific biological group of tumors characterized by a similar molecular aberration. And what we discussed with Dr. Ralf Herold, who leads the regulatory science at EMA, is all the efforts this regulatory agency does to work with us to make new drugs available for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
